A Pilot Study Evaluating the Effect of Artesunate on Glymphatic‐Related Fluid Transport in Parkinson's Disease Mouse Models In Vivo and Ex Vivo
CNS Neuroscience & Therapeutics · 2026-09 · 32 (9)
DOI: 10.1002/cns.71145 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 16.09.2026. Verfasst von Wan-Ting Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Glymphatic System, Artesunate, Parkinsonian Disorders. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Nanjing Science and Technology Innovation Project Research Foundation for Returned Overseas Students, Nanjing Medical University Science and Technology Development Project.
Abstract (Originalsprache)
Aims
Artesunate (ART) has shown neuroprotective potential, but its effects on glymphatic‐related fluid transport in Parkinson's disease (PD) remain unclear. This pilot study aimed to explore whether ART affects glymphatic‐related fluid transport in a PD mouse model and to assess the feasibility of evaluating these changes in vivo.
Methods
C57BL/6 WT and A53T mice ( n = 6 each) were divided into four groups (WT, WT + ART, A53T, and A53T + ART) and treated with ART or DMSO for 7 days. Glymphatic‐related fluid transport was assessed by dynamic MRI after intraventricular Gd‐DTPA injection. Immunofluorescence evaluated α‐syn, AQP4, and AQP4‐GFAP colocalization, while transmission electron microscopy (TEM) assessed astrocytic end‐feet integrity.
Results
ART was associated with regionally heterogeneous changes in tracer‐related MRI signal dynamics in both WT and A53T mice. In PD mice, ART was associated with partial restoration of AQP4 polarization in selected brain regions and improved perivascular astrocytic end‐feet morphology, accompanied by reduced α‐syn immunofluorescence signal in the substantia nigra.
Conclusion
ART was associated with regionally heterogeneous changes in glymphatic‐related fluid transport dynamics and AQP4 polarization in this pilot PD mouse study. These preliminary findings support further investigation of ART as a potential modulator of brain fluid transport‐related pathways in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of Radiology, Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center, Shanghai, China.
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Wan-Ting Han, Guang-Hui Xie, Xin-Ying Wu, Tong Fu
Förderung
- Natural Science Foundation of Jiangsu Province
- Nanjing Science and Technology Innovation Project Research Foundation for Returned Overseas Students
- Nanjing Medical University Science and Technology Development Project
Zitieren
APA
Han, W. T., Lu, W. H., Xu, H., Xie, G. H., Cao, Y., Wu, X. Y., Qiu, F., & Fu, T. (2026). A Pilot Study Evaluating the Effect of Artesunate on Glymphatic‐Related Fluid Transport in Parkinson's Disease Mouse Models In Vivo and Ex Vivo. CNS Neuroscience & Therapeutics, 32(9). https://doi.org/10.1002/cns.71145
Vancouver
Han WT, Lu WH, Xu H, Xie GH, Cao Y, Wu XY, et al. A Pilot Study Evaluating the Effect of Artesunate on Glymphatic‐Related Fluid Transport in Parkinson's Disease Mouse Models In Vivo and Ex Vivo. CNS Neuroscience & Therapeutics. 2026;32(9). doi:10.1002/cns.71145
BibTeX
@article{Han2026,
author = {Han, Wan-Ting and Lu, Wen-Hui and Xu, Hui and Xie, Guang-Hui and Cao, Yan and Wu, Xin-Ying and Qiu, Fan and Fu, Tong},
title = {A Pilot Study Evaluating the Effect of Artesunate on Glymphatic‐Related Fluid Transport in Parkinson's Disease Mouse Models In Vivo and Ex Vivo},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {9},
doi = {10.1002/cns.71145}
}
EUVIMED